News

SHANGHAI and ROCKVILLE, Md., May 26, 2021 — WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, […]

KENILWORTH, N.J., & ROCKVILLE, Md.–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and OncoImmune, a privately-held, […]

OncoImmune, Inc. announced today that it has dosed the first patient in the first-in-human clinical trial of ONC-392, its novel, […]

OncoImmune, Inc. announced today that its Investigational New Drug (“IND”) application for ONC-392, its novel, next generation anti-CTLA-4 antibody, has […]